In conclusion, our study underscores the potential utility of cytokine profiling, particularly IL-2, sPD-L1, and IL-23 into clinical practice to improve patient selection and personalize immunotherapy strategies in advanced NSCLC. Here, IL2 is linked to non-small cell lung carcinoma.